The Biotechnology Innovation Organization announced 30 layoffs as part of a restructuring, including the departure of senior leaders. AstraZeneca plans to nearly double revenue to $80 billion by 2030, launching 20 new medicines to increase revenue from $45.8 billion in 2023. The company’s investor update is its biggest in a decade. This news comes amid turnover at BIO, with four CEOs in four years. The update is viewed as significant, following AstraZeneca’s successful defense against a takeover attempt in 2014. Both developments signal changes in the biotech industry and pharmaceutical sector.
Source link
We’re watching BIO layoffs, AstraZeneca plans to double revenue
